SCIENCE & TECHNOLOGY PLURI HEALTH

SCIENCE &
TECHNOLOGY

Our cell technology is not just about developing cells, it’s also about harnessing the potential of these cells to treat challenging diseases.

Cell therapies have the potential to transform the care of chronic, debilitating illnesses, leading the world to an era of intelligent therapies focused on regenerating the body to its normal function. PLX cell-based product candidates do not require genetic matching prior to use, and to date have not been associated with clinically meaningful allosensitization or immune activation.

Our technology enables large scale expansion of
potent and unique placenta-derived stromal cells
in a tightly controlled manner. Cells from a single
placenta can treat more than 20,000 patients.

Our technology allows us to expand
placental-derived stromal cells and obtain the
highest quality and consistently reproducible
products. PluriHealth’s cell expansion platform
grows cells efficiently and reliably, with unique
batch-to-batch consistency in a highly cost-effective
process that can be applied to human cells.

Early on, we understood the need for a tightly
controlled, completely automated, efficient and
scalable cell manufacturing technology in order
to produce the highest quality cell therapy products
on a commercial scale. Our proprietary bioreactor
system provides a three dimensional (3D)
micro-environment for our cells that resembles the
human body. As a result, our cells remain healthy
and potent as they expand rapidly and transform
into cell therapeutics.

Advantages of Pluri Health Technology

PluriHealth cell technology platform benefits include:

Two decades of knowledge and experience in cell expansion using state-of-the-art 3D technology
platform

Off-the-shelf usability, requires no tissue matching

Chemistry, Manufacturing, and Control (CMC)approved for use in clinical studies by key regulators: the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Israeli Ministry of Health (MOH), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and Korean MFDA

Driving down costs with robust, scalable bioprocesses

GMP owned: In-house cGMP compliant manufacturing
facility for the commercial-scale production of
cell-based products

Rich IP portfolio with more than 130 active patents